The pathophysiology of GD - Current understanding and rationale for existing and emerging therapeutic approaches

Wiener Medizinische Wochenschrift

Volumn 160, Issue 23-24, 2010, Pages 594-599

  Hughes, Derralynn A ^a   Pastores, Gregory M ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chaperones; Enzyme replacement therapy; Gaucher disease; Glucocerebrosidase; Lysosomal storage disorder; Pathophysiology; Substrate reduction therapy

Indexed keywords

CALCIUM; CD14 ANTIGEN; COLONY STIMULATING FACTOR 1; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; IMIGLUCERASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; TALIGLUCERASE ALFA; TUMOR NECROSIS FACTOR ALPHA; VELAGLUCERASE ALFA;

ARTICLE; AUTOPHAGY; CALCIUM HOMEOSTASIS; ENDOPLASMIC RETICULUM STRESS; ENZYME REPLACEMENT; GAUCHER DISEASE; HUMAN; LIPID METABOLISM; LIPID STORAGE; MISSENSE MUTATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN FOLDING;

1-DEOXYNOJIRIMYCIN; ANIMALS; AUTOPHAGY; CALCIUM; CELL MEMBRANE; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; ENDOPLASMIC RETICULUM; ENZYME INHIBITORS; ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; GENE THERAPY; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; GLYCOLIPIDS; HOMEOSTASIS; HUMANS; MICE; OXIDATIVE STRESS; PROTEOSTASIS DEFICIENCIES;

EID: 78751500709     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0864-4     Document Type: Article

References (44)

1. M Jmoudiak AH Futerman 2005 Gaucher disease: pathological mechanisms and modern management Br J Haematol 129 178 188 1:CAS:528:DC%2BD2MXktl2htbc%3D 10.1111/j.1365-2141.2004.05351.x 15813845 (Pubitemid 40562438)
2. R Rozenberg DC Fox E Sobreira, et al. 2006 Detection of 12 new mutations in Gaucher disease Brazilian patients Blood Cells Mol Dis 37 204 209 1:CAS:528:DC%2BD28Xht1CisL7I 10.1016/j.bcmd.2006.09.004 17059888 (Pubitemid 44781086)
3. P Alfonso S Aznarez M Giralt, et al. 2007 Mutation analysis and genotype/phenotype relationships of Gaucher disease patients in Spain J Hum Genet 52 391 396 1:CAS:528:DC%2BD2sXks1yns7s%3D 10.1007/s10038-007-0135-4 17427031 (Pubitemid 46669310)
4. P Giraldo M Pocovi J Perez-Calvo, et al. 2000 Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics Haematologica 85 792 799 1:STN:280:DC%2BD3M%2FksFyksg%3D%3D 10942924
5. S Van Weely JM Aerts MB Van Leeuwen 1990 Function of oligosaccharide modification in glucocerebrosidase, a membrane-associated lysosomal hydrolase Eur J Biochem 191 669 677 1:CAS:528:DyaK3cXlsV2gs7w%3D 10.1111/j.1432-1033.1990. tb19173.x 2143986 (Pubitemid 20265776)
6. H Dvir M Harel AA McCarthy, et al. 2003 X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease EMBO Rep 4 704 709 1:CAS:528:DC%2BD3sXltVWhur4%3D 10.1038/sj.embor.embor873 12792654 (Pubitemid 36974756)
7. S Fabrega P Durand JP Mornon, et al. 2002 The active site of human glucocerebrosidase: structural predictions and experimental validations J Soc Biol 196 151 160 1:CAS:528:DC%2BD38Xos12ltbw%3D 12360744
8. V Koprivica DL Stone JK Park, et al. 2000 Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease Am J Hum Genet 66 1777 1786 1:CAS:528:DC%2BD3cXntV2jtbo%3D 10.1086/302925 10796875 (Pubitemid 30480085)
9. TH Taddei KA Kacena M Yang, et al. 2009 The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients Am J Hematol 84 208 214 10.1002/ajh.21362 19260119
10. E Beutler C West 2002 Polymorphisms in glucosylceramide (glucocerebroside) synthase and the Gaucher disease phenotype Isr Med Assoc J 4 986 988 1:CAS:528:DC%2BD38XpslerurY%3D 12489486
11. KA McEachern JB Nietupski WL Chuang, et al. 2006 AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease J Gene Med 8 719 729 1:CAS:528: DC%2BD28XnsVWjur0%3D 10.1002/jgm.901 16528760
12. IB Enquist E Nilsson JE Mansson, et al. 2009 Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease Stem Cells 27 744 752 1:CAS:528:DC%2BD1MXkvVKgu7g%3D 10.1634/stemcells.2008-0844 19056909
13. GA Grabowski S Gatt M Horowitz 1990 Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease Crit Rev Biochem Mol Biol 25 385 414 1:CAS:528:DyaK3MXltlaktb8%3D 10.3109/10409239009090616 2127241
14. F Ciaffoni M Tatti A Boe, et al. 2006 Saposin B binds and transfers phospholipids J Lipid Res 47 1045 1053 1:CAS:528:DC%2BD28XkvVCgsrw%3D 10.1194/jlr.M500547-JLR200 16461955 (Pubitemid 43764700)
15. T Pampols M Pineda ML Giros, et al. 1999 Neuronopathic juvenile glucosylceramidosis due to sap-C deficiency: clinical course, neuropathology and brain lipid composition in this Gaucher disease variant Acta Neuropathol (Berl) 97 91 97 1:CAS:528:DyaK1cXns1Wntbw%3D 10.1007/s004010050960 (Pubitemid 29132651)
16. O Nilsson G Hakansson S Dreborg, et al. 1982 Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III Clin Genet 22 274 279 1:STN:280:DyaL3s7gtlKisw%3D%3D 10.1111/j.1399-0004.1982.tb01445.x 7151312
17. R Gornati B Bembi X Tong, et al. 1998 Total glycolipid and glucosylceramide content in serum and urine of patients with Gaucher's disease type 3 before and after enzyme replacement therapy Clin Chim Acta 271 151 161 10.1016/S0009-8981(97)00241-6 9565330 (Pubitemid 28135213)
18. O Nilsson JE Mansson G Hakansson, et al. 1982 The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher's disease Biochim Biophys Acta 712 453 463 1:CAS:528: DyaL38Xlsl2ku7k%3D 7126619
19. R Gornati B Berra G Montorfano, et al. 2002 Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease J Inherit Metab Dis 25 47 55 1:CAS:528:DC%2BD38XjvVKlsb8%3D 10.1023/A:1015137917508 11999980 (Pubitemid 34303226)
20. TM Cox 2001 Gaucher's disease - an exemplary monogenic disorder QJM 94 399 402 1:STN:280:DC%2BD3Mvks1yqug%3D%3D 10.1093/qjmed/94.8.399 11493715
21. LA Boven M van Meurs RG Boot, et al. 2004 Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages Am J Clin Pathol 122 359 369 1:CAS:528:DC%2BD2cXotFyhurg%3D 10.1309/ BG5VA8JRDQH1M7HN 15362365
22. N Pennelli F Scaravilli F Zacchello 1969 The morphogenesis of Gaucher cells investigated by electron microscopy Blood 34 331 347 1:STN:280: DyaF1M3ms1ejsQ%3D%3D 5804023
23. GM Pastores 1997 Gaucher's disease. Pathological features Baillieres Clin Haematol 10 739 749 1:STN:280:DyaK1c7lvFaqtA%3D%3D 10.1016/S0950-3536(97)80037- 6 9497861 (Pubitemid 28022206)
24. V Barak M Acker B Nisman, et al. 1999 Cytokines in Gaucher's disease Eur Cytokine Netw 10 205 210 1:CAS:528:DyaK1MXlsFWiurk%3D 10400826
25. CE Hollak L Evers JM Aerts, et al. 1997 Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease Blood Cells Mol Dis 23 201 212 1:STN:280:DyaK2szotlelsw%3D%3D 10.1006/bcmd.1997.0137 9236158 (Pubitemid 27469455)
26. A Brautbar D Elstein G Pines, et al. 2004 Effect of enzyme replacement therapy on gammopathies in Gaucher disease Blood Cells Mol Dis 32 214 217 1:CAS:528:DC%2BD2cXntVGqug%3D%3D 10.1016/j.bcmd.2003.10.007 14757437 (Pubitemid 38147719)
27. GM Pastores 2010 Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease Curr Opin Investig Drugs 11 472 478 1:CAS:528:DC%2BC3cXnt1Khu7c%3D 20336596
28. GM Pastores 2010 Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease BioDrugs 24 41 47 1:CAS:528:DC%2BC3cXislSrtrs%3D 10.2165/11318540-000000000-00000 20055531
29. Bracoud L, Ahmad H, Brill-Almon E, et al. Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model. Blood Cells Mol Dis, in press, 2010
30. GA Grabowski NW Barton G Pastores, et al. 1995 Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources Ann Intern Med 122 33 39 1:STN:280:DyaK2M%2FnslaisA%3D%3D 7985893
31. R Schiffmann EJ Fitzgibbon C Harris, et al. 2008 Randomized, controlled trial of miglustat in Gaucher's disease type 3 Ann Neurol 64 514 522 10.1002/ana.21491 19067373
32. E Lukina N Watman EA Arreguin, et al. 2010 Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study Blood 116 4095 4098 1:CAS:528:DC%2BC3cXhsFCiu7fJ 10.1182/blood-2010-06-293902 20713962
33. I Ron M Horowitz 2005 ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity Hum Mol Genet 14 2387 2398 1:CAS:528:DC%2BD2MXpsFams7w%3D 10.1093/hmg/ddi240 16000318 (Pubitemid 41418000)
34. A Velayati WH Yu E Sidransky 2010 The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders Curr Neurol Neurosci Rep 10 190 198 1:CAS:528:DC%2BC3cXht1CjsLrM 10.1007/s11910-010-0102-x 20425034
35. M Deganuto MG Pittis A Pines, et al. 2007 Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress J Cell Physiol 212 223 235 1:CAS:528: DC%2BD2sXmtVWkurg%3D 10.1002/jcp.21023 17443679 (Pubitemid 46867605)
36. PM Campeau M Rafei MN Boivin, et al. 2009 Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome Blood 114 3181 3190 1:CAS:528:DC%2BD1MXhtlShtbjK 10.1182/blood-2009- 02-205708 19587377
37. T Farfel-Becker E Vitner H Dekel, et al. 2009 No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease Hum Mol Genet 18 1482 1488 1:CAS:528:DC%2BD1MXktV2htbo%3D 10.1093/hmg/ddp061 19193629
38. R Steet S Chung WS Lee, et al. 2007 Selective action of the iminosugar isofagomine, a pharmacological chaperone for mutant forms of acid-beta-glucosidase Biochem Pharmacol 73 1376 1383 1:CAS:528: DC%2BD2sXjsVGitLc%3D 10.1016/j.bcp.2006.12.015 17217920 (Pubitemid 46452579)
39. L Diaz J Bujons J Casas, et al. 2010 Click chemistry approach to new N-substituted aminocyclitols as potential pharmacological chaperones for Gaucher disease J Med Chem 53 5248 5255 1:CAS:528:DC%2BC3cXnsFyhs70%3D 10.1021/jm100198t 20557054
40. D Pelled S Trajkovic-Bodennec E Lloyd-Evans, et al. 2005 Enhanced calcium release in the acute neuronopathic form of Gaucher disease Neurobiol Dis 18 83 88 1:CAS:528:DC%2BD2MXkslOhug%3D%3D 10.1016/j.nbd.2004.09.004 15649698 (Pubitemid 40092898)
41. 2+ increases enhance mutant glucocerebrosidase proteostasis Nat Chem Biol 6 424 432 1:CAS:528:DC%2BC3cXlslyqtL8%3D 10.1038/nchembio.368 20453863
42. Y Sun GA Grabowski 2010 Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease Autophagy 6 648 649 10.4161/auto.6.5.12047 (Epub ahead of print)
43. M Tatti M Motta R Salvioli 2010 Autophagy in Gaucher disease due to saposin C deficiency Autophagy 7 94 95 10.4161/auto.7.1.13884
44. A Ballabio 2009 Disease pathogenesis explained by basic science: lysosomal storage diseases as autophagocytic disorders Int J Clin Pharmacol Ther 47 Suppl 1 S34 S38 1:CAS:528:DC%2BC3cXhtVWls7w%3D 20040309